BRUGIA, MARCO
 Distribuzione geografica
Continente #
EU - Europa 1.321
NA - Nord America 1.288
AS - Asia 360
AF - Africa 3
Totale 2.972
Nazione #
US - Stati Uniti d'America 1.283
RU - Federazione Russa 540
IT - Italia 242
PL - Polonia 218
IE - Irlanda 120
SG - Singapore 95
CN - Cina 91
HK - Hong Kong 89
SE - Svezia 78
JO - Giordania 41
AT - Austria 35
IN - India 31
DE - Germania 28
CH - Svizzera 17
GB - Regno Unito 11
FI - Finlandia 10
ES - Italia 8
VN - Vietnam 8
CA - Canada 4
TR - Turchia 4
UA - Ucraina 4
CI - Costa d'Avorio 3
NL - Olanda 3
BE - Belgio 2
FR - Francia 2
NO - Norvegia 2
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
Totale 2.972
Città #
Santa Clara 310
Warsaw 214
Chandler 123
Dublin 120
Fairfield 100
Ashburn 93
Singapore 82
Florence 56
Hong Kong 56
Seattle 51
Cambridge 49
Houston 48
Woodbridge 45
Wilmington 36
Vienna 35
Beijing 33
Altamura 32
Lawrence 28
Ann Arbor 25
Shanghai 22
Moscow 21
Bremen 20
Princeton 20
New York 19
Bern 17
Mumbai 17
Boston 15
Boardman 14
Buffalo 14
Medford 12
Pune 12
Milan 11
Barcelona 8
Dong Ket 8
Rome 8
Helsinki 7
Kent 7
Brescia 6
Falls Church 5
Los Angeles 5
Munich 5
Amandola 4
Cinisello Balsamo 4
Naples 4
San Diego 4
Yubileyny 4
Abidjan 3
Alba 3
Ancona 3
London 3
Mykolayiv 3
San Marco Evangelista 3
Sesto Fiorentino 3
Shenzhen 3
Andover 2
Argelato 2
Brusaporto 2
Brussels 2
Carmignano 2
Cernusco sul Naviglio 2
Dearborn 2
Forlì 2
Formia 2
Frankfurt Am Main 2
Guangzhou 2
Hangzhou 2
Hillsboro 2
Istanbul 2
Laurel 2
Mileto 2
Newark 2
Norwalk 2
Oslo 2
Padova 2
Palermo 2
Parma 2
Phoenix 2
Pisa 2
Radomsko 2
San Giovanni Valdarno 2
Siena 2
Surrey 2
Taranto 2
Toronto 2
Turin 2
Varese 2
Vico Equense 2
Washington 2
West Jordan 2
Aprilia 1
Baotou 1
Central District 1
Kilburn 1
Kunming 1
Lahore 1
Lappeenranta 1
Lisbon 1
Lucca 1
New Bedfont 1
Oggiono 1
Totale 1.934
Nome #
Emerging drugs in refractory colorectal cancer 265
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 192
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 141
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 139
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 135
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 122
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 120
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 118
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 115
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 112
Physical exercise and eating habits in cancer survivors 111
Regorafenib also can cause osteonecrosis of the jaw 101
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 100
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 93
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 93
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 90
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 89
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 88
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 78
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 72
Results of the observational prospective RealFLOT study 70
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 64
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 64
Somatostatin analogs in pregnant patients with neuroendocrine tumor 62
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 62
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 62
Current status and future perspectives in HER2 positive advanced gastric cancer 61
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 55
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 52
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 45
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 31
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 29
null 3
Totale 3.034
Categoria #
all - tutte 10.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.620


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020224 0 0 0 0 32 29 35 31 27 26 37 7
2020/2021287 21 25 2 36 43 30 22 15 27 33 20 13
2021/2022138 4 7 5 3 2 10 1 20 11 13 16 46
2022/2023651 32 110 18 60 45 121 70 55 80 9 20 31
2023/2024401 9 25 37 18 20 64 26 81 8 34 34 45
2024/20251.113 64 178 114 339 418 0 0 0 0 0 0 0
Totale 3.034